vs
BIODESIX INC（BDSX）与GRAIL, Inc.（GRAL）财务数据对比。点击上方公司名可切换其他公司
GRAIL, Inc.的季度营收约是BIODESIX INC的1.5倍（$43.6M vs $28.8M）。BIODESIX INC净利率更高（-13.8% vs -227.5%，领先213.6%）。BIODESIX INC同比增速更快（40.8% vs 14.0%）。BIODESIX INC自由现金流更多（$692.0K vs $-63.9M）。过去两年BIODESIX INC的营收复合增速更高（39.3% vs 27.7%）
BIODESIX INC是一家专注于肿瘤与感染病领域的分子诊断企业，开发并商业化创新血液检测解决方案，主要服务北美地区的医疗机构、生物制药合作伙伴及患者，核心业务包括辅助临床决策的个性化医疗产品。
GRAIL是2015年成立的美国生物技术企业，总部位于加利福尼亚州门洛帕克，核心业务是研发面向无症状人群的癌症早期筛查检测产品。该公司最初是基因测序企业Illumina旗下的初创子公司，2021年被Illumina全资收购。
BDSX vs GRAL — 直观对比
营收规模更大
GRAL
是对方的1.5倍
$28.8M
营收增速更快
BDSX
高出26.8%
14.0%
净利率更高
BDSX
高出213.6%
-227.5%
自由现金流更多
BDSX
多$64.6M
$-63.9M
两年增速更快
BDSX
近两年复合增速
27.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $28.8M | $43.6M |
| 净利润 | $-4.0M | $-99.2M |
| 毛利率 | — | — |
| 营业利润率 | -6.8% | -285.4% |
| 净利率 | -13.8% | -227.5% |
| 营收同比 | 40.8% | 14.0% |
| 净利润同比 | 51.8% | -2.2% |
| 每股收益（稀释后） | $-3.35 | $-2.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDSXGRAL
| Q4 25 | $28.8M | $43.6M | ||
| Q3 25 | $21.8M | $36.2M | ||
| Q2 25 | $20.0M | $35.5M | ||
| Q1 25 | $18.0M | $31.8M | ||
| Q4 24 | $20.4M | $38.3M | ||
| Q3 24 | $18.2M | $28.7M | ||
| Q2 24 | $17.9M | $32.0M | ||
| Q1 24 | $14.8M | $26.7M |
净利润BDSXGRAL
| Q4 25 | $-4.0M | $-99.2M | ||
| Q3 25 | $-8.7M | $-89.0M | ||
| Q2 25 | $-11.5M | $-114.0M | ||
| Q1 25 | $-11.1M | $-106.2M | ||
| Q4 24 | $-8.3M | $-97.1M | ||
| Q3 24 | $-10.3M | $-125.7M | ||
| Q2 24 | $-10.8M | $-1.6B | ||
| Q1 24 | $-13.6M | $-218.9M |
营业利润率BDSXGRAL
| Q4 25 | -6.8% | -285.4% | ||
| Q3 25 | -32.4% | -346.2% | ||
| Q2 25 | -48.6% | -446.9% | ||
| Q1 25 | -50.9% | -482.5% | ||
| Q4 24 | -32.5% | -358.0% | ||
| Q3 24 | -47.3% | -640.5% | ||
| Q2 24 | -46.0% | -5133.8% | ||
| Q1 24 | -74.4% | -851.1% |
净利率BDSXGRAL
| Q4 25 | -13.8% | -227.5% | ||
| Q3 25 | -40.0% | -245.8% | ||
| Q2 25 | -57.3% | -320.7% | ||
| Q1 25 | -61.8% | -333.6% | ||
| Q4 24 | -40.4% | -253.8% | ||
| Q3 24 | -56.5% | -438.7% | ||
| Q2 24 | -60.3% | -4958.8% | ||
| Q1 24 | -91.9% | -819.3% |
每股收益（稀释后）BDSXGRAL
| Q4 25 | $-3.35 | $-2.37 | ||
| Q3 25 | $-1.16 | $-2.46 | ||
| Q2 25 | $-0.08 | $-3.18 | ||
| Q1 25 | $-0.08 | $-3.10 | ||
| Q4 24 | $-5.02 | $-1.49 | ||
| Q3 24 | $-1.40 | $-3.94 | ||
| Q2 24 | $-0.08 | $-51.06 | ||
| Q1 24 | $-0.14 | $-7.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $19.0M | $249.7M |
| 总债务越低越好 | $50.0M | — |
| 股东权益账面价值 | $-2.5M | $2.6B |
| 总资产 | $87.5M | $2.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BDSXGRAL
| Q4 25 | $19.0M | $249.7M | ||
| Q3 25 | $16.6M | $126.9M | ||
| Q2 25 | $20.7M | $127.4M | ||
| Q1 25 | $17.6M | $133.9M | ||
| Q4 24 | $26.2M | $214.2M | ||
| Q3 24 | $31.4M | $853.6M | ||
| Q2 24 | $42.2M | $958.8M | ||
| Q1 24 | $11.5M | $199.7M |
总债务BDSXGRAL
| Q4 25 | $50.0M | — | ||
| Q3 25 | $50.0M | — | ||
| Q2 25 | $50.0M | — | ||
| Q1 25 | $40.0M | — | ||
| Q4 24 | $40.0M | — | ||
| Q3 24 | $40.0M | — | ||
| Q2 24 | $40.1M | — | ||
| Q1 24 | $40.1M | — |
股东权益BDSXGRAL
| Q4 25 | $-2.5M | $2.6B | ||
| Q3 25 | $-1.7M | $2.2B | ||
| Q2 25 | $1.1M | $2.3B | ||
| Q1 25 | $11.1M | $2.4B | ||
| Q4 24 | $20.9M | $2.5B | ||
| Q3 24 | $27.9M | $2.6B | ||
| Q2 24 | $36.3M | $2.7B | ||
| Q1 24 | $-5.5M | — |
总资产BDSXGRAL
| Q4 25 | $87.5M | $2.9B | ||
| Q3 25 | $88.7M | $2.6B | ||
| Q2 25 | $87.7M | $2.7B | ||
| Q1 25 | $86.2M | $2.8B | ||
| Q4 24 | $97.2M | $3.0B | ||
| Q3 24 | $102.7M | $3.1B | ||
| Q2 24 | $115.8M | $3.3B | ||
| Q1 24 | $87.2M | — |
负债/权益比BDSXGRAL
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 43.95× | — | ||
| Q1 25 | 3.62× | — | ||
| Q4 24 | 1.92× | — | ||
| Q3 24 | 1.44× | — | ||
| Q2 24 | 1.10× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $778.0K | $-63.8M |
| 自由现金流经营现金流 - 资本支出 | $692.0K | $-63.9M |
| 自由现金流率自由现金流/营收 | 2.4% | -146.5% |
| 资本支出强度资本支出/营收 | 0.3% | 0.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-23.5M | $-299.9M |
8季度趋势，按日历期对齐
经营现金流BDSXGRAL
| Q4 25 | $778.0K | $-63.8M | ||
| Q3 25 | $-8.9M | $-63.2M | ||
| Q2 25 | $-6.6M | $-77.0M | ||
| Q1 25 | $-8.6M | $-95.0M | ||
| Q4 24 | $-4.1M | — | ||
| Q3 24 | $-10.7M | $-104.6M | ||
| Q2 24 | $-18.6M | $-171.8M | ||
| Q1 24 | $-15.3M | $-207.3M |
自由现金流BDSXGRAL
| Q4 25 | $692.0K | $-63.9M | ||
| Q3 25 | $-8.9M | $-63.6M | ||
| Q2 25 | $-6.6M | $-77.3M | ||
| Q1 25 | $-8.7M | $-95.1M | ||
| Q4 24 | $-4.9M | — | ||
| Q3 24 | $-10.9M | $-105.6M | ||
| Q2 24 | $-20.5M | $-173.2M | ||
| Q1 24 | $-15.5M | $-209.8M |
自由现金流率BDSXGRAL
| Q4 25 | 2.4% | -146.5% | ||
| Q3 25 | -41.0% | -175.8% | ||
| Q2 25 | -33.1% | -217.6% | ||
| Q1 25 | -48.3% | -298.6% | ||
| Q4 24 | -24.2% | — | ||
| Q3 24 | -60.1% | -368.4% | ||
| Q2 24 | -114.3% | -541.7% | ||
| Q1 24 | -104.9% | -785.3% |
资本支出强度BDSXGRAL
| Q4 25 | 0.3% | 0.2% | ||
| Q3 25 | 0.2% | 1.1% | ||
| Q2 25 | 0.3% | 1.0% | ||
| Q1 25 | 0.4% | 0.2% | ||
| Q4 24 | 4.1% | — | ||
| Q3 24 | 1.3% | 3.4% | ||
| Q2 24 | 10.7% | 4.3% | ||
| Q1 24 | 1.6% | 9.5% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDSX
| Diagnostic Tests | $25.1M | 87% |
| Development Services | $3.6M | 13% |
GRAL
| Screening Revenue | $42.3M | 97% |
| Developmental Services Revenue | $1.3M | 3% |
